Review
Rev Diabet Stud,
2009,
6(1):13-36 |
DOI 10.1900/RDS.2009.6.13 |
Adenosine Monophosphate-Activated Protein Kinase (AMPK) as a New Target for Antidiabetic Drugs: A Review on Metabolic, Pharmacological and Chemical Considerations
Arie Gruzman, Gali Babai, Shlomo Sasson
Department of Pharmacology, School of Pharmacy, Faculty of Medicine, The Hebrew University, Jerusalem 91120, Israel
Address correspondence to: Shlomo Sasson, e-mail: ShlomoSasson@huji.ac.il
Manuscript submitted April 10, 2009; resubmitted May 7, 2009; accepted May 9, 2009.
Keywords: diabetes, hyperglycemia, AMP, antihyperglycemic, drug target, energy metabolism, glucose transport, skeletal muscle, D-xylose
Abstract
In view of the epidemic nature of type 2 diabetes and the substantial rate of failure of current oral antidiabetic drugs the quest for new therapeutics is intensive. The adenosine monophosphate-activated protein kinase (AMPK) is an important regulatory protein for cellular energy balance and is considered a master switch of glucose and lipid metabolism in various organs, especially in skeletal muscle and liver. In skeletal muscles, AMPK stimulates glucose transport and fatty acid oxidation. In the liver, it augments fatty acid oxidation and decreases glucose output, cholesterol and triglyceride synthesis. These metabolic effects induced by AMPK are associated with lowering blood glucose levels in hyperglycemic individuals. Two classes of oral antihyperglycemic drugs (biguanidines and thiazolidinediones) have been shown to exert some of their therapeutic effects by directly or indirectly activating AMPK. However, side effects and an acquired resistance to these drugs emphasize the need for the development of novel and efficacious AMPK activators. We have recently discovered a new class of hydrophobic D-xylose derivatives that activates AMPK in skeletal muscles in a non insulin-dependent manner. One of these derivatives (2,4;3,5-dibenzylidene-D-xylose-diethyl-dithioacetal) stimulates the rate of hexose transport in skeletal muscle cells by increasing the abundance of glucose transporter-4 (GLUT-4) in the plasma membrane through activation of AMPK. This compound reduces blood glucose levels in diabetic mice and therefore offers a novel strategy of therapeutic intervention strategy in type 2 diabetes. The present review describes various classes of chemically-related compounds that activate AMPK by direct or indirect interactions and discusses their potential for candidate antihyperglycemic drug development.
Fulltext:
HTML
, PDF
(453KB)
This article has been cited by other articles:
|
Molecular mechanisms for anti-aging by natural dietary compounds
Pan MH, Lai CS, Tsai ML, Wu JC, Ho CT
Mol Nutr Food Res 2012. 56(1):88-115
|
|
|
Peptide scaffolds: flexible molecular structures with diverse therapeutic potentials
Deshmukh R, Purohit HJ
Int J Peptide Res Ther 2012. In press
|
|
|
AMPK protects proximal tubular cells from stress-induced apoptosis by an ATP-independent mechanism: potential role of Akt activation
Lieberthal W, Zhang L, Patel VA, Levine JS
Am J Physiol Renal Physiol 2011. 301(6):F1177-F1192
|
|
|
Computer-aided drug design for AMP-activated protein kinase activators
Wang Z, Huo J, Sun L, Wang Y, Jin H, Yu H, Zhang L, Zhou L
Curr Comput Aided Drug Des 2011. 7(3):214-227
|
|
|
Effect of chromium enriched fermentation product of barley and brewer's yeast and its combination with rosiglitazone on experimentally induced hyperglycaemia in mice
Cekic V, Vasovic V, Jakovljevic V, Lalosevic D, Capo I, Mikov M, Sabo A
Srp Arh Celok Lek 2011. 139(9-10):610-618
|
|
|
Antihyperglycaemic activity of 2,4:3,5-dibenzylidene-D-xylose-dithioacetal in diabetic mice
Gruzman A, Elgart A, Viskind O, Billauer H, Dotan S, Cohen G, Mishani E, Hoffman A, Cerasi E, Sasson S
J Cell Mol Med 2011. In press
|
|
|
Nutrigenomics of neuradaptogen amino-acid-therapy and neurometabolic optimizers: overcoming carbohydrate bingeing and overeating through neurometabolic mechanisms
Blum K, Bagchi D, Bowirrat A, Downs BW, Waite RL, Giordano J, Morse S, Madigan M, Downs JM, Braverman ER, Polanin M, Barh D, Fornari F, Simpatico T
Funct Food Health Dis 2011. 9:310-378
|
|
|
Key regulators of mitochondrial biogenesis are increased in kidneys of growth hormone receptor knockout (GHRKO) mice
Gesing A, Bartke A, Wang F, Karbownik-Lewinska M, Masternak MM
Cell Biochem Funct 2011. 29(6):459-467
|
|
|
Targeting the AMP-regulated kinase family to treat diabetes: a research update
Sun G, Rutter GA
Diabetes Manag 2011. 1(3):333-347
|
|
|
Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma
Siddique A, Kowdley KV
Clin Liver Dis 2011. 15(2):281-296
|
|
|
Curcumin protects hepatic stellate cells against leptin-induced activation in vitro by accumulating intracellular lipids
Tang Y, Chen A
Endocrinology 2010. 151(9):4168-4177
|
|
|
Binding of cordycepin monophosphate to AMP-activated protein kinase and its effect on AMP-activated protein kinase activation
Wang Z, Wang X, Qu K, Zhu P, Guo N, Zhang R, Abliz Z, Yu H, Zhu H
Chem Biol Drug Des 2010. 76(4):340-344
|
|
|
AMP-Activated protein kinase as a target for preconditioning in transplantation medicine
Bouma HR, Ketelaar ME, Yard BA, Ploeg RJ, Henning RH
Transplantation 2010. 90(4):353-358
|
|
|
Does LKB1 Mediate Activation of Hepatic AMP-Protein Kinase (AMPK) and Sirtuin1 (SIRT1) After Roux-en-Y Gastric Bypass in Obese Rats?
Peng Y, Rideout DA, Rakita SS, Gower WR Jr, You M, Murr MM
J Gastrointest Surg 2010. 14(2):221-228
|
|
|
Curcumin activates AMPK and suppresses gluconeogenic gene expression in hepatoma cells
Kim T, Davis J, Zhang AJ, He X, Mathews ST
Biochem Biophys Res Commun 2009. 388(2):377-382
|
|
|